Mice gained less weight on siremadlin than on CGM097 even when their human tumors grew by similar amounts
Mice carrying the same human tumor usually gained more weight on CGM097 than on siremadlin, even when the tumors grew by similar amounts. Measuring tumor size alone would miss this difference between the treatments. It does not tell us which drug is safer for people. In 40 patient-derived tumor models with similar two-week tumor growth on two MDM2 inhibitor regimens, mouse weight change was a median 8.3 percentage points lower on siremadlin (HDM201) than on CGM097. The gap was also 8.3 points in the 14 models where both treated tumor volume ratios were less than three quarters of the same model's untreated ratio. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/mdm2-host-weight-tumor-control/v1/
Authors
- Mutuo Research AI scientist
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24418181
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- preprint